We are very pleased to announce that the Supervisory Board has appointed Dr. Hans van Schijndel as Member of the Board of HAL Allergy Holding B.V. in the position of Chief Research & Development Officer (Chief R&D Officer) as of 1 February 2020.
With this appointment, the Board of Directors is now complete. Next to Dr. Hans van Schijndel, in charge of the R&D program, the Board consists of Florian Rösch being the Chief Commercial & Financial Officer and Dr. Eize de Boer, the Chief Operations Officer taking care of Production and Quality Assurance.
Dr. Hans van Schijndel
Chief Research & Development Officer HAL Allergy Holding B.V.
Dr. Hans van Schijndel has a PhD in Biochemistry and is employed by HAL Allergy since 2012. In his career at HAL Allergy he served as Principal Scientist/Head of Pre-clinical Research and was engaged in several bio-technological projects including the Therapieallergene-Verordnung (TAV) program. In his position of Chief R&D Officer he will take care of this TAV-Program and significant novel developments in the food and inhalative sector including clinical development to enable the treatment of Peanut and Ragweed allergies.
HAL Allergy specializes in immunotherapy, desensitization and therapeutic treatment of all allergies mainly caused by tree and grass pollens and mites with the help of preparations that can be administered sublingually or subcutaneously. The company works intensively in collaboration with its sales organizations, distributors and internationally acclaimed research institutes to bring out the best possible combination of knowledge and experience.
As Chief Technology Officer, Dr. Hans van Schijndel also joins the Board of Directors of HALIX B.V.
As of the 1 February the composition of the Board is as follows: Alex Huybens, Chief Operations Officer, Florian Rösch, Chief Financial Officer and Dr. Hans van Schijndel, Chief Technology Officer.
HALIX is a corporate venture and spin-off of HAL Allergy, serving customers as a contract development and manufacturing organization (CDMO). HALIX leverages advanced biopharmaceutical technologies and provides its customers the full range from the first development steps to start of commercial production after successful registration of products.
The Board of Directors
HAL Allergy Group
About HAL Allergy
HAL Allergy specializes in immunotherapy, desensitization and therapeutic treatment of all allergies mainly caused by tree and grass pollens and mites with the help of preparations that can be administered orally or subcutaneously. The company works intensively in collaboration with its sales organizations, distributors and internationally acclaimed research institutes to bring out the best possible combination of knowledge and experience. The company focuses on the core group of allergy experts from the specialties of Ear Nose & Throat, Dermatology, Pediatrics and Pulmonology. HAL Allergy has the most modern and state‑of‑the‑art production facility at its main site in the Leiden Bio Science Park in the Netherlands. Currently their products are marketed in sixteen countries. Moreover this leading manufacturer of therapeutic and diagnostic agents for allergies has sales organizations in all the major European markets including Germany, Poland, Austria, Italy and Spain. More information is available on: www.hal‑allergy.com.
The main shareholder of HAL Allergy Group is Droege Group AG, based in Düsseldorf, Germany.
About Droege Group
Droege Group (founded in 1988) is an independent advisory and investment company under full family ownership. The company acts as a specialist for tailor-made transformation programs aiming to enhance corporate value. Droege Group combines its corporate family-run structure and capital strength into a family-equity business model. The group carries out direct investments with its own equity in corporate spin-offs and medium-sized companies in “special situations”. With the guiding principle “execution – following the rules of art”, the group is a pioneer in execution-oriented corporate development. Droege Group follows a focused investment strategy based on current megatrends (knowledge, connectivity, prevention, demography, specialization, future work, shopping 4.0). Enthusiasm for quality, innovation and speed determines the company’s actions. In recent years Droege Group has successfully positioned itself in domestic and international markets and operates in 30 countries.
More information is available on: www.droege-group.com
Contact HAL Allergy
Monique Lutgens – Manager Corporate Communications
Tel. + 31 (0)88 1959010